Advances in RNA Vaccines and Therapeutics: MIT Researchers Optimize Production Process

Recent breakthroughs in RNA vaccines and therapeutics have motivated the need for process engineering strategies to optimize the in vitro transcription reaction for RNA synthesis. Researchers at the Massachusetts Institute of Technology (MIT) have developed a mechanistic model for fed-batch IVT, which is a promising technique for achieving optimal RNA production while minimizing the use of expensive reagents. The model-based optimization approach can produce twice as much RNA as a heuristic approach and has been shown to prevent magnesium phosphate crystallization during the IVT reaction.

Key Takeaways:

• MIT researchers have developed a mechanistic model for fed-batch IVT to optimize RNA production and minimize reagent use.
• The model-based optimization approach can produce twice as much RNA as a heuristic approach.
• The approach has been shown to prevent magnesium phosphate crystallization during the IVT reaction.
• The research has been peer-reviewed and published in the journal ChemBioChem.
• The study was supported by the U.S. Food and Drug Administration.
• The researchers involved in the study are Soroush Ahmadi, Nathan Merica Stover, Jacob Rosenfeld, Francesco Destro, Allan S. Myerson, and Richard D. Braatz.

Statistics:

• The model-based optimization approach can produce twice as much RNA as a heuristic approach.
• The approach has been shown to prevent magnesium phosphate crystallization during the IVT reaction.
• The study was funded by the U.S. Food and Drug Administration.

Sources:

• NewsRx. Research Conducted at Massachusetts Institute of Technology Has Provided New Information about Vaccines (Model-Based Optimization of Fed-Batch In Vitro Transcription). Vaccine Weekly. October 22, 2025; p 342.
• ChemBioChem. "Model-Based Optimization of Fed-Batch In Vitro Transcription." (2025)